Document:

AGREEMENT
      OF COLLABORATION

     

    THIS AGREEMENT
      OF COLLABORATION (the
      “Agreement”) is made the 5th
      day of
      March, 2007 (“Effective Date”) between:

    

    
      	
              (1)

            	
              SHANGHAI
                BIOCHIP COMPANY, LTD. a corporation having its principal office at
                151
                Libing Road, Pudong, Shanghai, 201203, China (“SBC”), and USA office
                (MaxyBio Corporation) at 675 US Highway One, North Brunswick, New
                Jersey
                08902, USA ; and

            

    

     

    
      	
              (2)

            	
              RESPONSE
                GENETICS INC., a company incorporated in the State of Delaware, whose
                principal place of business is situated at 1640 Marengo Street, Suite
                600,
                Los Angeles, CA 90033, USA (“RGI”).

            

    

     

    RECITALS

     

    WHEREAS,
      SBC
      is
      engaged in the business of providing pharmacogenomics, bioinformatics and
      genomics testing and data; 

     

    WHEREAS,
      RGI
      is
      engaged in the business of providing pharmaceuticals and biotechnology companies
      with pharmacogenomic analysis services; and

     

    WHEREAS,
      RGI
      deems it advisable to collaborate with SBC and for SBC to provide testing,
      consulting and advisory services, and SBC is willing to provide such services
      to
      RGI,

     

    

    IT
      IS HEREBY AGREED AS FOLLOWS:

    

    

    DEFINITIONS
      AND INTERPRETATIONS

     

    
      	 	
              1

            	
              In
                this Agreement the following expressions shall have the following
                meanings:

            

    

     

     

    
      
        
          Portions
            of this Exhibit were omitted and have been filed separately with the
            Secretary
            of the Commission pursuant to the Company’s application requesting confidential
            treatment under Rule 406 of the Securities Act.

           

        

      

      
        1

        
          

        

      

      
         

      

    

     

    
      	 	
              1.1

            	
              “Affiliate”
                with respect to a person shall mean any other person that directly,
                or
                indirectly through one of more intermediaries, controls, is controlled
                by
                or is under common control with such person; for the purposes of
                this
                clause 1.1 only, “control” and, with correlative meanings, the terms
                “controlled by” and “under common control with”, shall mean (a) the
                possession, directly or indirectly, of the power to direct the management
                or policies of a person, whether through the ownership of voting
                securities, by contract or otherwise, and/or (b) the ownership, directly
                or indirectly, of at least fifty percent (50%) of the voting securities
                or
                other ownership interest of a
                person.

            

    

     

    
      	 	
              1.2

            	
              “Agreement”
                means this Agreement between SBC and RGI for the supply of Services
                by
                SBC.

            

    

     

    
      	 	
              1.3

            	
              “Confidential
                Information”
                shall mean any and all commercial and technical information relating
                to
                any of the existing or planned products, businesses, research and/or
                development activities, customers and suppliers of either Party whether
                in
                written, verbal or any other form, tangible or intangible, which
                either
                Party may acquire or may have access from time to time, provided
                such
                information is marked as “Confidential
                and Proprietary”
                and provided that information which is orally disclosed shall be
                confirmed
                in writing within 30 days from oral disclosure. Confidential Information
                includes and is not limited to: (a) any information generated in
                connection with the provision of the Services (such as the results
                or
                findings thereof and the contents of any report) under this Agreement,
                (b)
                information concerning inventions, discoveries, concepts, ideas,
                techniques, processes, designs, specifications, drawings, diagrams,
                models, samples, flow charts, computer programs, algorithms, data,
                databases, studies, mathematical calculations, finances and plans,
                customer lists, business plans, contracts, marketing plans, production
                plans, distribution plans, system implementation plans, business
                concepts,
                supplier information, business procedures and business operations
                and all
                materials related thereto; (c) the existence, contents or terms of
                this
                Agreement, (d) all know-how and intellectual property, (e) all unpublished
                copyrightable material, (f) any use, variation, application, reduction
                to
                practice, or any discussion and any other communication thereof regarding
                or relating to the Information, and (g) any information concerning
                how any
                part of the above information is related to and/or fits together
                with any
                other part of the above information, or any other technology or business;
                Notwithstanding the foregoing, the Parties agree that any and all
                data,
                reports, laboratory work sheets, results, materials or information
                provided by either Party or its Affiliates or Third Parties on behalf
                of a
                Party and any other documents or information furnished to a Party,
                or to
                which a Party is given access, by the other Party or its Affiliates
                or
                such Third Parties in connection with the performance of this Agreement,
                or prepared or generated by a Party in connection with performing
                any and
                all Studies hereunder, shall be deemed to be the Confidential Information
                of the Party which owns such disclosed
                information.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          2

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.4

            	
              “Effective
                Date”
                means March 5, 2007, the date that this Agreement of Collaboration
                was
                executed; 

            

    

     

    
      	 	
              1.5

            	
              “Party”
                shall mean SBC or RGI as the context requires and “Parties”
                shall mean both SBC and RGI;

            

    

     

    
      	 	
              1.6

            	
              “Person”
                and words importing persons shall be construed as to include individuals,
                firms, bodies corporate, joint ventures, governments, states or agencies
                of state or any undertaking (whether or not having separate legal
                personality and irrespective of the jurisdiction in or under the
                laws of
                which it was incorporated or
                exists);

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          3

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.7

            	
              “Purpose”
                shall mean the establishment of a business collaboration between
                RGI and
                SBC in China for providing Testing Services.

            

    

     

    
      	 	
              1.8

            	
              “Relevant
                Staff”
                shall mean employees and sub-contractors involved in providing the
                Services under this Agreement; 

            

    

    
       

      
        	 	
                1.9

              	
                “Services”
                  means the services to be provided by SBC pursuant to this Agreement
                  (as
                  amended from time to time in accordance with the provisions of
                  this
                  Agreement) and such other services as may from time to time be
                  agreed upon
                  by RGI and SBC, including Testing Services, consultation and tissue
                  storage, in connection with this Agreement and as further detailed
                  and
                  agreed upon in a Protocol pursuant to Article 1 below;
                  

              

      

       

    

    
      	 	
              1.10

            	
              “Term”
                means that this Agreement shall commence on the Effective Date and
                shall
                continue until the fifth (5th)
                anniversary of the Effective Date (“Initial Term”), unless sooner
                terminated in an authorized manner. This agreement will thereafter
                automatically renew for successive three year terms unless either
                party
                gives notice of its intent not to renew 90 days in advance of such
                renewal
                date. Termination will not end work as necessary to support customer
                clinical trials in progress. 

            

    

     

    
      	 	
              1.11

            	
              “Testing
                Services”
                means, among other things, conducting molecular-based tumor tissue
                profiling using a proprietary and patented process developed by RGI
                which
                involves a complex molecular analysis of specific molecular markers
                that
                provides valuable tumor specific gene expression information obtained
                from
                a paraffin preserved fresh or frozen tissue sample and molecular-based
                tumor tissue profiling using EGF-receptor immunohistochemistry (“IHC”),
                HER-2 IHC, estrogen receptor IHC, progesterone receptor IHC and/or
                fluorescence in situ hybridization analysis of molecular markers
                of gene
                expression obtained from a tissue
                sample.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          4

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.12

            	
              “Third
                Party”
                shall mean any Person who is not a Party hereto or any of their
                Affiliates

            

    

     

    
      	 	
              2

            	
              References
                to recitals, clauses and, if applicable, schedules are to the recitals
                and
                clauses of and, if applicable, the schedules to, this Agreement.
                To the
                extent that there is conflict between or ambiguity relating to any
                schedules to this Agreement and the remainder of this Agreement,
                the
                wording of the schedules shall
                prevail.

            

    

     

    
      	 	
              3

            	
              Any
                schedules to this Agreement form part of this Agreement and shall
                have the
                same force and effect as if expressly set out in the body of the
                Agreement
                and any reference to the Agreement shall include the schedules. Schedules
                may not be added to this Agreement except by the express written
                consent
                of both Parties.

            

    

     

    
      	 	
              4

            	
              Words
                denoting the singular shall include the plural and vice versa and
                words
                denoting any gender shall include all genders unless the context
                otherwise
                requires.

            

    

     

    
      	 	
              5

            	
              A
                reference to any Party shall include a reference to the legal successors
                to the whole or a substantial part of its undertaking and its permitted
                assignees.

            

    

     

    
      	 	
              6

            	
              References
                to any statute or statutory provision shall, unless the context otherwise
                requires, be construed as a reference to that statute or provision
                as from
                time to time amended, consolidated, modified, extended, re-enacted
                or
                replaced.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          5

          
            

          

        

        
           

        

      

       

    

    
      	 	
              7

            	
              The
                headings preceding the text of the various provisions of this Agreement
                are for convenience of reference only and are not intended to, nor
                do
                they, define, limit or in any other way describe the scope of this
                Agreement or the intent of the provisions
                hereof.

            

    

     

    ARTICLE
      1

     

    STATEMENT
      OF WORK; STUDY DIRECTOR

     

    
      	 	
              1.1

            	
              Collaboration
                Services; Statement of
                Work

            

    

     

    
      	 	
              1.1.1

            	
              SBC
                and RGI agree to perform a study or studies from time to time as
                requested
                by RGI or SBC which will involve Testing Services (hereinafter referred
                to
                as “Collaboration Services”). SBC and RGI shall
                carry out their respective responsibilities for the
                Collaboration Services
                in
                accordance with a
                Statement of Work in the form of Exhibit
                A attached
                hereto (“SOW”).
                Each SOW will not be effective unless it has been agreed upon in
                writing
                by both Parties
                and such agreement will
                not be unreasonably withheld. SBC and RGI shall carry out their respective
                responsibilities for the Collaboration Services in accordance with
                the
                respective SOW in a timely manner. 

            

    

     

    
      	 	
              1.1.2

            	
              If
                requested by RGI, SBC shall consult with RGI to assist RGI in developing
                any study design in a manner consistent with current regulatory
                guidelines. RGI represents that any such study design and/or the
                results
                from any such study shall satisfy the requirements of the U.S. Food
                and
                Drug Administration (“FDA”) and the European Medicines Agency (“EMEA”) at
                the time the study design is completed.

            

    

     

    
      	 	
              1.2

            	
              Study
                Management

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          6

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.2.1

            	
              RGI
                shall appoint a general manager of the collaboration with qualified
                technical and management skills (“General Manager”). The General Manager
                will be responsible for directing personnel in how to perform the
                Collaboration Services and the analysis of customer samples. The
                General
                Manager shall have full access to all records, information and data
                related to the performance of Collaboration Services. The General
                Manager
                will also have the right of access to all laboratory and storage
                space
                used for Collaboration Services, to communicate with any Relevant
                Staff
                concerning the performance of Collaboration Services and to observe
                performance of the Collaboration Services. RGI will be responsible
                for the
                costs of the General Manager.

            

    

     

    
      	 	
              1.2.2

            	
              SBC
                will appoint a vice-general manager (“Vice-General Manager”). The
                Vice-General Manager will be responsible for managing Relevant Staff
                for
                the Collaboration Services and coordinating with the General Manager
                to
                perform the Collaboration Services. SBC will be responsible for the
                costs
                of the Vice-General Manager.

            

    

     

    

    
      	
              1.3

            	
              Collaboration Management

            

    

     

    
      	 	
              1.3.1

            	
              The
                collaboration will be managed by a planning committee of six members,
                including two members designated by each party, the General Manager,
                and
                the Vice General Manager of the collaboration. The planning committee
                will
                meet during year one (1) of the collaboration in order to ensure
                that
                Collaboration Services can be provided to meet the needs of customers.
                The
                planning committee will meet at such times as may be agreed by the
                parties, and may conduct meetings by telephone conference. The planning
                committee may review the status of projects, earning/cost information
                for
                individual project and financial plans. The planning committee may
                discuss, examine and evaluate how to prioritize spending to purchase
                or
                lease additional equipment and facilities as required by customer’s
                projects or GLP/CLIA regulations from any budget resulting from advanced
                payment from customers or profits from the collaboration’s contracts. The
                planning committee may also discuss quarterly-based or annual financial
                plan to enhance the collaboration’s GLP/CLIA capability and capacity.
                

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          7

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.4

            	
              Commencement
                of Operations

            

    

     

    
      	 	
              1.4.1

            	
              RGI
                will provide training both in the US and China as reasonably required
                to
                enable SBC to conduct Collaboration Services and analysis of customer
                samples using RGI’s technology, methods and protocols. Such methods and
                protocols will be treated as Confidential Information of RGI conveyed
                to
                SBC under a license solely for the duration of the
                Term.

            

    

     

    
      	 	
              1.4.2

            	
              SBC
                will use its best efforts and will take any and all steps necessary
                to
                become qualified as necessary so that the results of analysis performed
                by
                the collaboration will be usable in clinical trials and regulatory
                submissions in major markets worldwide, with such qualification to
                be
                achieved within [***] of the effective date of the
                agreement.

            

    

     

    
      	 	
              1.4.3

            	
              Each
                party will bear their respective costs associated with training and
                commencement of operations.

            

    

     

    
      	
              1.5

            	
              Corrective
                Measures

            

    

     

    
      	 	
              1.5.1

            	
              If,
                at any time during the term of this Agreement, SBC becomes aware
                that the
                applicable SOW was not followed, or that SBC otherwise made a material
                error or mistake in conducting Collaboration Services, SBC agrees
                to
                notify RGI of such occurrence in writing promptly following the day
                such
                discovery is made. Upon receipt of such notice, RGI will
                notify SBC in writing, within a reasonable time, whether corrective
                measures which may include retesting are required to ensure validity
                of
                results. SBC agrees to promptly implement necessary corrective measures.
                The retest data will be reported by SBC to RGI within a reasonable
                time
                from the receipt by SBC of notification from RGI that retesting is
                required.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          8

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.6

            	
              License
                Grant.

            

    

     

    
      	 	
              1.6.1

            	
              Subject
                to SBC’s performance of its obligations under this Agreement, RGI grants
                SBC the exclusive right to perform Collaboration Services in China.
                

            

    

     

    
      	 	
              1.6.2

            	
              RGI
                will grant an exclusive license in China to its technology and know
                how
                related to RGI’s proprietary RNA extraction technologies with FFPE tissue
                (“RGI’s Technology”), to be used by SBC for the performance of
                Collaboration Services to benefit the collaboration. Subject to consent
                from the University of Southern California (“USC”), RGI will grant SBC a
                sublicense to patents that USC licenses to RGI. All of the rights
                granted
                to SBC are subject to Roche Diagnostics’ worldwide exclusive license of
                RGI’s FFPE technology for the use, manufacture and sale of in
                vitro
                diagnostic test kits. 

            

    

     

    
      	 	
              1.6.3

            	
              RGI
                shall be under no obligation to file, prosecute, maintain, defend
                or
                enforce any of the Intellectual Property or any intellectual property
                related to RGI’s Technology, individually or in the aggregate. RGI shall
                have sole discretion concerning the filing, prosecution, maintenance,
                defense and enforcement of the Intellectual Property or any intellectual
                property related to RGI’s Technology, including the cost for such actions.
                If SBC becomes aware of any alleged, threatened or actual infringement,
                misappropriation, imitation, illegal use or misuse of RGI’s Intellectual
                Property or any intellectual property related to RGI’s Technology, SBC
                shall promptly notify RGI of such
                Infringement.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          9

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.6.4

            	
              SBC
                will perform RNA extraction from FFPE tissue samples exclusively
                for RGI
                during the term of this Agreement. SBC further agrees to not offer
                services for RNA extraction in paraffin based tissues using RGI’s
                proprietary RNA extraction technology following any termination of
                the
                agreement(s).

            

    

     

    
      	 	
              1.7

            	
              Operational
                Structure

            

    

     

    
      	 	
              1.7.1

            	
              The
                Parties may each promote the collaboration in China with the goal
                of
                developing contracts with customers to provide pharmacogenomics analysis
                services using FFPE tissue samples. RGI will use “RGI in China at SBC” to
                promote the collaboration’s service to RGI’s customer. SBC will use “SBC
                is RGI’s exclusive service provider or distributor in China” to promote
                the collaboration’s services to SBC’s customers. SBC’s USA Office (MaxyBio
                Corporation, 675 US Highway One, North Brunswick, NJ 08902) will
                represent
                SBC in co-promotion and contract development. All proposed contracts
                from
                SBC/MaxyBio using Testing Services will be explicitly approved in
                writing
                by RGI before they are executed. No contract may be executed without
                this
                approval. A SOW for the relevant contract work using RGI’s proprietary
                technologies will be signed between Parties. If SBC wishes to contract
                with a company in China to perform Testing Services on less than
                [***]
                samples obtained in China, it may propose a template agreement to
                the
                company in the form attached as Exhibit B to this Agreement (including
                a
                completed SOW and Pricing Schedule associated with such template
                agreement. RGI agrees not to unreasonably withhold its consent to
                executing such an agreement. Any proposed changes to the template
                agreement must be approved in writing in advance by RGI. If such
                changes
                are not acceptable to RGI, then no modification may be made to the
                proposed template agreement.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          10

          
            

          

        

        
           

        

      

       

    

    
      	 	
              1.7.2

            	
              Either
                party may retain agents or representatives to act on its behalf,
                provided
                that neither party may authorize an agent to act on behalf of the
                other
                party without the express written consent of that party. Promotional
                materials used by either party which refer to the collaboration or
                the
                other party must be approved by both parties prior to use.
                

            

    

     

    
      	 	
              1.7.3

            	
              The
                Parties will agree on the content and timing of any public release
                or
                announcement of their collaboration and this Agreement (“Official
                Announcement”). Neither Party will make any public announcement concerning
                their collaboration or this agreement prior to the Official Announcement.
                RGI may report to the U.S. Securities and Exchange Commission (“SEC”) any
                information regarding this Agreement which it reasonably deems advisable
                or necessary.

            

    

     

    ARTICLE
      2

     

    COMPENSATION
      

     

    
      	 	
              2.1

            	
              A
                Gross Margin, defined as fees collected from Collaboration Services
                performed by SBC minus any Shared Costs as defined below, will be
                calculated for all such collected fees.

            

    

     

    
      	 	
              2.2

            	
              Shared
                Costs shall be defined as any [***]; and the costs of [***] agreed
                upon in
                advance by the Parties. If an SOW requires the use of an microarray
                (or
                gene chip), [***] for the purposes of calculating gross margin. The
                [***]
                shall be the best price that SBC or RGI can
                obtain.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          11

          
            

          

        

        
           

        

      

       

    

    
      	 	
              2.3

            	
              Other
                than Shared Costs, the Parties will be individually and separately
                responsible for their own costs. No costs other than Shared Costs
                will be
                deducted from fees collected for Collaboration Services when calculating
                the Gross Margin.

            

    

     

    
      	 	
              2.4

            	
              For
                the avoidance of doubt, RGI will be individually and separately
                responsible for the following costs which will not be deducted from
                fees
                collected for Collaboration Services when calculating the Gross Margin:
                

            

    

     

    
      	 	
              2.4.1

            	
              Royalty
                payments to third parties under existing licensing agreements, and
                license
                fees for RGI’s intellectual
                property

            

    

     

    
      	 	
              2.4.2

            	
              Salary
                of the General Manager

            

    

     

    
      	 	
              2.4.3

            	
              RGI’s
                costs associated with the analysis of raw data from test results
                

            

    

     

    
      	 	
              2.4.4

            	
              RGI’s
                costs associated with generating final reports to
                customers

            

    

     

    
      	 	
              2.4.5

            	
              RGI’s
                costs of responding to customer inquiries regarding the results of
                analysis the data and the report of test results
                

            

    

     

    
      	 	
              2.4.6

            	
              RGI’s
                costs associated with providing training and assistance with laboratory
                setup. 

            

    

     

    
      	 	
              2.5

            	
              For
                the avoidance of doubt, SBC will be individually and separately
                responsible for the following costs which will not be deducted from
                fees
                collected for Collaboration Services when calculating the Gross Margin:
                

            

    

     

    
      	 	
              2.5.1

            	
              The
                initial cost of lab equipment, as well as any additional equipment
                resulting from increases in volume of
                business

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          12

          
            

          

        

        
           

        

      

       

    

    
      	 	
              2.5.2

            	
              Maintenance
                or service fees and expenses for the existing testing
                equipment

            

    

     

    
      	 	
              2.5.3

            	
              Cost
                of reagents

            

    

     

    
      	 	
              2.5.4

            	
              Qualified
                laboratory space, including any rent for such
                space

            

    

     

    
      	 	
              2.5.5

            	
              Laboratory
                personnel, including the Vice-General Manager and necessary FTE personnel
                to perform Collaboration Services

            

    

     

    
      	 	
              2.5.6

            	
              SBC’s
                costs of responding to customer inquiries regarding the performance
                of the
                testing, storage of the samples and other record
                keeping

            

    

     

    
      	 	
              2.5.7

            	
              SBC’s
                costs associated with training and commencement of
                operations.

            

    

     

    

    
      	 	
              2.6

            	
              The
                Gross Margin will be divided and paid on a quarterly basis as follows:
                [***]% to Response Genetics and [***]% to SBC.

            

    

     

    
      	 	
              2.7

            	
              Payments
                made to SBC will be paid directly to SBC’s USA office (MaxyBio
                Corporation). 

            

    

     

    
      	 	
              2.8

            	
              Each
                party will have the right to audit the financial records including
                contracts of the other to confirm earnings/costs incurred in connection
                with respect to the collaboration.

            

    

     

    
      	 	
              2.9

            	
              RGI
                agrees to provide SBC with excerpts of relevant contracts with Third
                Parties as an Appendix to the SOW, which show the price that RGI will
                receive per sample for Testing Services that SBC will perform under
                this
                Agreement. 

            

    

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          13

          
            

          

        

        
           

        

      

       

    

    ARTICLE
      3

     

    Performance
      of the Services - Service Provisions

     

    
      	 	
              3.1

            	
              SBC
                will collect, receive and store samples from customers and conduct
                testing
                and analysis according to RGI’s methods and
                protocols.

            

    

     

    
      	 	
              3.2

            	
              SBC
                will report test results to RGI, who will confirm the analysis and
                generate final results. The final reports will bear both RGI and
                SBC’s
                name prominently as contributors. RGI will communicate with customers
                and
                respond to customer inquiries regarding the results of the analysis
                of the
                data and the reports of test results. SBC will cooperate with responding
                to customer inquiries regarding the performance of the assays, storage
                of
                the samples and other record
                keeping.

            

    

     

    
      	 	
              3.3

            	
              SBC
                will establish suitable, qualified laboratory facilities for the
                performance of Collaboration Services. SBC will perform the Collaboration
                Services in accordance with good laboratory art. SBC also will comply
                with
                the applicable laws, regulations, and guidelines governing the performance
                of the Collaboration Services, including those relating to Good Laboratory
                Practices. SBC further will comply with all laws, regulations and
                guidelines applicable to the care and use of experimental animals.
                In
                addition, all animals used in projects covered by this Agreement
                shall be
                provided humane care and treatment in accordance with acceptable
                current
                veterinary practices. SBC will obtain any necessary authorizations
                and
                permissions for all equipment and reagents which it uses in performing
                Collaboration Services. 

            

    

     

    
      	 	
              3.4

            	
              SBC
                shall provide facilities, supplies and staff necessary to complete
                each
                Study as provided in the applicable SOW, as it may be modified as
                provided
                herein, and in accordance with the terms of this Agreement. SBC will
                bear
                the costs of providing such facilities, supplies and staff. Examples
                of
                SBC’s contributions to the collaboration
                include:

            

    

     

    
      	 	
              3.4.1

            	
              Existing
                facilities, equipment and lab certifications as necessary for the
                analysis
                of samples, including additions to the facilities required to satisfy
                business volume.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          14

          
            

          

        

        
           

        

      

       

    

    
      	 	
              3.4.2

            	
              SBC’s
                proprietary SOPs, know-how and technologies for SBC’s existing platforms
                including microarrays from Affymetrix, Agilent, Illumina, and in-house
                generated tissue/blood banks, tissue arrays, cDNA/oligo arrays,
                sequencing, RT-PCR, TaqMan, IHC/FISH, DNA/RNA extractions, GLP compliant
                sample collection and management system and clinical trial central
                laboratory database system, and bioinformatics/IT, to the extent
                necessary
                for the collaboration.

            

    

     

    
      	 	
              3.4.3

            	
              SBC’s
                existing capabilities in genomics, proteomics, pharmacogenomics and
                pharmacogenetics for gene expression/molecular profiling, SNP
                discovery/genotyping and biomarker analysis using samples from
                pre-clinical studies or clinical trials, to the extent necessary
                for the
                collaboration

            

    

     

    
      	 	
              3.4.4

            	
              Suitably
                qualified personnel as necessary to perform the Collaboration
                Services.

            

    

     

    

    
      	 	
              3.5

            	
              RGI
                will provide to SBC, [***], proprietary reagents required for the
                preparation of samples. SBC will be responsible for all requirements
                related to the import of those reagents into China. If RGI determines
                that
                it would be preferable for SBC to obtain certain reagents, RGI will
                so
                advise SBC and SBC will make reasonable efforts to obtain such reagents.
                

            

    

     

    
      	 	
              3.6

            	
              RGI’s
                representatives may visit SBC’s laboratory and premises at reasonable
                times, on reasonable prior notice, and with reasonable frequency
                during
                normal business hours to observe the progress of any Collaboration
                Services, and any and all information and results derived therefrom.
                SBC
                shall assist RGI in scheduling such
                visits.

            

    

     

    
      	 	
              3.7

            	
              All
                reports prepared by SBC hereunder shall be prepared in a format specified
                in the applicable SOW. RGI shall have access to all documentation,
                records, raw data, specimens or other work product generated during
                the
                performance of each Study. SBC agrees to maintain appropriate records
                in
                paper or magnetic form, in a manner which complies with regulatory
                requirements.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          15

          
            

          

        

        
           

        

      

       

    

    
      	 	
              3.8

            	
              SBC
                agrees to comply with all provisions of the Generic Drug Enforcement
                Act
                of 1992. SBC further agrees to submit to RGI, upon request upon completion
                or termination of the Collaboration Services, a certification that
                neither
                SBC nor any of its employees has been debarred by the FDA under the
                provisions of the Act and that SBC did not use in any capacity in
                connection with the Collaboration Services any individual debarred
                by the
                FDA under the provisions of the above referenced
                Act.

            

    

     

    
      	 	
              3.9

            	
              Should
                applicable government regulatory requirements be changed during the
                term
                of this Agreement, SBC shall make reasonable efforts to satisfy the
                new
                requirements. In the event that compliance with such new regulatory
                requirements necessitates a change in the SOW for a Study, SBC shall
                submit to RGI a revised technical and cost proposal for RGI’s acceptance
                prior to making any changes in the SOW for such
                Study.

            

    

     

    
      	 	
              3.10

            	
              In
                the event of a conflict in government regulations, RGI shall, upon
                request
                by SBC, designate which regulations shall be followed by SBC in its
                performance of a particular study.

            

    

     

    
      	 	
              3.11

            	
              SBC
                agrees to use reasonable care in safeguarding, inventorying and handling
                all SOW data, materials and supporting documentation (hereinafter
                collectively termed “Study Archives”) originating from any SOW conducted
                under this Agreement by SBC, whether written or physical (such as
                notebooks, original or raw data, protocols, interim or final report
                copies). The Study Archives shall be considered to be Confidential
                Information of RGI. SBC will maintain the samples provided to it
                for
                testing under this Agreement in accordance with the usual and customary
                standards for maintaining such materials. Upon request by RGI, SBC
                will
                provide sample materials to RGI or a copy of documents from the Study
                Archives, at RGI’s expense. To the extent that samples are transferred to
                RGI, responsibility for maintaining such samples will then be undertaken
                by RGI. The samples and Study Archives are to be retained and archived
                by
                SBC for a period of not less than [***] following the completion
                of the
                relevant SOW. 

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          16

          
            

          

        

        
           

        

      

       

    

    
      	 	
              3.12

            	
              SBC
                agrees to maintain all electronic information or data on secure systems
                which are dedicated to information and data generated under this
                Agreement. SBC shall also cooperate with RGI to implement, use and
                maintain any software or computer systems specified by
                RGI.

            

    

     

    

    
      	 	
              3.13

            	
              Following
                the end of the relevant [***] retention period, RGI further agrees
                that no
                samples or records originating from any Collaboration Services conducted
                under this Agreement and retained in SBC’s possession as Study Archives
                will be permanently disposed of or destroyed by SBC without the prior
                written permission of RGI. RGI agrees that such written permission
                will
                not be unreasonably withheld; provided, however, that in lieu of
                the
                granting of permission for such disposal, RGI shall have the right
                at the
                time such permission for disposal is requested by SBC to claim such
                materials and to have SBC transmit such materials to RGI, by a carrier
                of
                RGI’s choice and at RGI’s expense. In the event SBC requests such
                permission to dispose of the samples or Study Archives from RGI under
                the
                provisions of notice contained in this Agreement, and no response
                is
                received from RGI within [***], SBC shall
                be deemed to have received from RGI permission for permanent
                disposal.

            

    

     

    
      	 	
              3.14

            	
              RGI may,
                at a reasonable time upon reasonable prior notice, obtain access
                to the
                samples and Study Archives, provided that RGI complies
                with SBC’s reasonable access and control procedures relating to such
                materials.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          17

          
            

          

        

        
           

        

      

       

    

    
      	 	
              3.15

            	
              SBC
                represents that each of its personnel, employees, agents, representatives,
                subcontractors or invitees who shall perform any Study hereunder shall
                abide by the provisions of Article
                3
                hereof. SBC agrees that each of its personnel, employees, agents,
                representatives, subcontractors or invitees who shall perform any
                Study
                hereunder shall be at least eighteen (18) years old or legal age,
                whichever is older.

            

    

     

    ARTICLE
      4

     

    Confidentiality

     

    
      	 	
              4.1

            	
              Confidentiality
                and Non-Use.
                Save as otherwise provided in this Agreement, any Confidential Information
                which is disclosed by or on behalf of either Party (the “Disclosing
                Party”) to the other Party (the “Receiving Party”) at any time after the
                date of this Agreement shall remain the property of the Disclosing
                Party
                and the Receiving Party hereby
                undertakes:

            

    

     

    
      	 	
              4.1.1

            	
              to
                use the Confidential Information received from the Disclosing Party
                and
                subject to the provisions of Section 4 hereto, solely and exclusively
                for
                the Purpose; and

            

    

     

    
      	 	
              4.1.2

            	
              to
                maintain the confidentiality of the Confidential Information and
                not to
                disclose it directly or indirectly to any other company, organization,
                individual or Third Party, save as permitted by Section 4.2;
                and

            

    

     

    
      	 	
              4.1.3

            	
              at
                the request of the Disclosing Party to return, delete or destroy
                all
                copies of the Confidential Information, in whatever form it is held,
                provided that the Receiving Party may retain one copy of the Confidential
                Information for the sole purpose of determining its obligations under
                this
                Agreement but may make no further use of such Confidential Information
                whatsoever.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          18

          
            

          

        

        
           

        

      

       

    

    
      	 	
              4.2

            	
              Notwithstanding
                Section 4.1, if SBC is the Receiving Party, it may disclose Confidential
                Information to any of its relevant staff who need to know the Confidential
                Information in order to fulfill the Purpose, provided that SBC shall
                procure that each such person to whom or which Confidential Information
                is
                to be disclosed:

            

    

     

    
      	 	
              4.2.1

            	
              is
                made aware of the obligations contained in this Agreement prior to
                such
                disclosure; and

            

    

     

    
      	 	
              4.2.2

            	
              agrees
                to abide by such terms of this Agreement as if it were a Party to
                it.

            

    

     

    
      	 	
              4.3

            	
              Nothing
                in Section 4.1 shall preclude disclosure of any Confidential Information
                required by any governmental, quasi-governmental or regulatory agency
                or
                authority or court entitled by law to disclosure of the same, or
                which is
                required by law to be disclosed. The Receiving Party shall promptly
                notify
                the Disclosing Party when such requirement to disclose has arisen
                to
                enable the Disclosing Party to seek an appropriate protective order
                and to
                make known to the said agency or authority or court the proprietary
                nature
                of the Confidential Information and to make any applicable claim
                of
                confidentiality in respect thereof. The Receiving Party agrees to
                co-operate in any appropriate action which the Disclosing Party may
                decide
                to take. If the Receiving Party is advised to make a disclosure in
                accordance with this Section 4.3 it shall only make a disclosure
                to the
                extent to which it is obliged.

            

    

     

    
      	 	
              4.4

            	
              The
                provisions of clause 4.1 shall not apply to any Confidential Information
                which:

            

    

     

    
      	 	
              4.4.1

            	
              the
                Receiving Party can demonstrate by its written records, was already
                in the
                possession of the Receiving Party and at its free use and disposal
                or
                generally and conveniently available to the public prior to its disclosure
                by the Disclosing Party hereunder (through in each case no fault
                of the
                Receiving Party or any of its Affiliates or no breach of this Agreement
                by
                the Receiving Party); or

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          19

          
            

          

        

        
           

        

      

       

    

    
      	 	
              4.4.2

            	
              is
                purchased or otherwise legally acquired by or becomes available to
                the
                Receiving Party at any time from a Third Party which is not prohibited
                from disclosing such Confidential Information; or
                

            

    

     

    
      	 	
              4.4.3

            	
              the
                Receiving Party can demonstrate by its written records was developed
                by or
                for the Receiving Party independently of the disclosure of Confidential
                Information by the Disclosing Party or its
                Affiliates.

            

    

     

    
      	 	
              4.5

            	
              Each
                of the Parties agrees that damages may not be an adequate remedy
                for
                breach of this Article 4 and that, accordingly, each Party shall
                be
                entitled to seek injunctive or other equitable relief for breach
                of this
                Article 4.

            

    

     

    ARTICLE
      5

     

    Intellectual
      Property

     

    
      	 	
              5.1

            	
              Except
                as otherwise provided herein, all title to any and all inventions,
                improvements and data, whether or not patentable, and copyrightable
                works,
                which result from the performance of Collaboration Services hereunder
                shall reside with RGI, subject to the remaining provisions of this
                Article
                5. SBC hereby assigns all right, title and interest to the Intellectual
                Property to RGI. 

            

    

     

    
      	 	
              5.2

            	
              SBC
                will make reasonable efforts to disclose to RGI all inventions and
                improvements (whether patentable or not) and all copyrightable works
                made
                by it which are governed by this Section 5.1. SBC agrees, upon RGI’s
                written request, to cooperate at RGI’s expense in formally assigning title
                to RGI to such inventions, improvements and copyrightable works,
                and to
                assist RGI in obtaining patent or copyright protection to such
                intellectual property.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          20

          
            

          

        

        
           

        

      

       

    

    
      	 	
              5.3

            	
              Subject
                to the remaining provisions of this Article 5, SBC agrees that all
                original works of authorship prepared by or for SBC in the performance
                of
                Collaboration Services hereunder shall be works for hire, and RGI
                shall
                own such works and all copyrights therein. For any original such
                works of
                authorship that, under the copyright laws of the United States, may
                not be
                considered works for hire, SBC agrees to reasonably cooperate with
                RGI in
                protecting its rights in such works. Such works shall be deemed to
                be the
                property of RGI, and shall be included in the Confidential Information
                of
                RGI under this Agreement. 

            

    

     

    
      	 	
              5.4

            	
              RGI
                owns, and SBC acknowledges RGI’s ownership of, (i) the Testing Services,
                including RGI’s proprietary process for analyzing the samples and
                producing the gene expression values, and all of the materials which
                comprise same, and any accompanying patent information owned by RGI,
                (ii)
                all intellectual property associated therewith (the “Intellectual
                Property”), and (iii) any algorithms or scales created and used by RGI in
                producing or developing the gene expression values (“algorithms”), and
                agrees that it shall not do or suffer to be done any act or thing
                or
                undertake any action anywhere that in any manner might infringe,
                or impair
                the validity, scope, or title of RGI in the Testing Services, algorithms
                or Intellectual Property which may be owned by RGI at any time. It
                is
                understood that neither SBC nor any Affiliate shall acquire or claim
                title
                to the Testing Services, algorithms, research and development, or
                the
                Intellectual Property by virtue of this Agreement, including any
                improvements or modifications thereto which are developed during
                the
                course of RGI’s performance under the Agreement, the Parties intending
                that all utilization of the Testing Services, algorithms and relating
                Intellectual Property by SBC shall at all times inure to the exclusive
                benefit of RGI.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          21

          
            

          

        

        
           

        

      

       

    

    
      	 	
              5.5

            	
              Each
                Party retains full ownership of its intellectual property which pre-exists
                the Effective Date. 

            

    

     

    
      	 	
              5.6

            	
              The
                Parties will retain all ownership rights to their technology, including
                but not limited to its processes and protocols for the testing of
                samples
                and any improvements to those processes or protocols.
                

            

    

     

    
      	 	
              5.7

            	
              The
                Parties will retain all right, title and interest to their own software.
                The agreement will prohibit the making of any unauthorized copies
                of RGI’s
                software or of attempting to access or reverse engineer its source
                code.

            

    

     

    
      	 	
              5.8

            	
              The
                Parties will observe all copyright in written material, including
                computer
                software, belonging to the other Party or any third Party, will not
                make
                any unauthorized copies of such material or
                software.

            

    

     

    
      	 	
              5.9

            	
              Each
                Party acknowledges that the other Party owns certain inventions,
                processes, know-how, trade secrets, improvements and other intellectual
                property which have been independently developed by each Party and
                which
                relate to that Party’s business or operations. It is acknowledged that the
                intellectual property owned by either Party on the Effective Date
                of this
                Agreement will remain the exclusive property of the owning
                Party.

            

    

     

    ARTICLE
      6

     

    Relationship
      of the Parties

     

    
      	 	
              6.1

            	
              It
                is understood that in the performance of this Agreement RGI will
                be acting
                in the capacity of an independent contractor and that nothing in
                this
                Agreement shall be construed as creating any contract of employment
                or
                relationship of principal and agent between RGI and SBC or RGI or
                any of
                the Relevant Staff.

            

    

     

    
      	 	
              6.2

            	
              SBC
                shall perform this Agreement solely as an independent contractor,
                and as
                such shall select, engage and discharge its employees and otherwise
                direct
                and control the performance of the Collaboration Services. Neither
                SBC nor
                anyone employed by it shall be, represent, act, or purport to act
                as, or
                be deemed to be, the agent, representative, employee, or servant
                of RGI
                nor shall RGI nor anyone employed by it be, represent, act, or purport
                to
                act as, or be deemed to be, the agent, representative, employee,
                or
                servant of SBC.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          22

          
            

          

        

        
           

        

      

       

    

    
      	 	
              6.3

            	
              Neither
                SBC nor RGI shall have authority to make any statement, representation,
                or
                commitment of any kind or to take any action binding upon the other
                Party
                without the other Party's prior written
                authorization.

            

    

     

    ARTICLE
      7

     

    Representation
      and Warranties - Indemnification

     

    
      	 	
              7.1

            	
              SBC
                represents and warrants that SBC and the Relevant
                Staff:

            

    

     

    
      	 	
              7.1.1

            	
              have
                the appropriate level of expertise and qualifications and the necessary
                ability to undertake the work required under this Agreement;
                and

            

    

     

    
      	 	
              7.1.2

            	
              are
                not prevented or restricted by any obligations owed to a third Party
                or
                otherwise in any way from performing the
                Services.

            

    

     

    
      	 	
              7.2

            	
              Each
                Party represents and warrants that it has the right to enter into
                this
                Agreement and is not in conflict with any third Party obligation
                during
                the performance of the Study under this Agreement.
                

            

    

     

    
      	 	
              7.3

            	
              Each
                Party represents and warrants that the individual signing on its
                behalf
                has actual authority to enter into this Agreement and bind the Party
                with
                respect to the provisions of this Agreement.

            

    

     

    
      	 	
              7.4

            	
              In
                addition to any other indemnification provided herein, SBC agrees
                to
                indemnify, defend and hold RGI and its affiliates, shareholders,
                officers,
                directors, employees, agents, successors and assigns harmless from
                and
                against any and all claims, suits, actions, liabilities, losses,
                costs,
                reasonable attorneys' fees, expenses, judgments or damages, whether
                ordinary, special or consequential (collectively, the “Indemnified
                Amounts”),
                arising out of (i) SBC's negligence in the performance of any Study,
                (ii)
                any wrongful acts or omissions in the performance by SBC of any Study,
                whether such actions are of RGI, its employees, agents, representatives,
                subcontractors or invitees or (iii) any material breach of this Agreement
                by SBC, its employees, agents, representatives, subcontractors or
                invitees.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          23

          
            

          

        

        
           

        

      

       

    

    
      	 	
              7.5

            	
              In
                addition to any other indemnification provided herein, RGI agrees
                to
                indemnify, defend and hold SBC and its affiliates, shareholders,
                officers,
                directors, employees, agents, successors and assigns harmless from
                and
                against any and all Indemnified Amounts arising out of (i) RGI's
                negligence in the conduct of the activities to be performed by RGI
                under
                this Agreement, (ii) any wrongful acts or omissions in the conduct
                of the
                activities to be performed by RGI under this Agreement, whether such
                actions are of RGI, its employees, agents, representatives, subcontractors
                or invitees or (iii) any material breach of this Agreement by RGI,
                its
                employees, agents, representatives, subcontractors or
                invitees.

            

    

     

    
      	 	
              7.6

            	
              Where
                claims relate to those by third Parties and in the event either Party
                incurs, or expects to incur expenses, damages, claims or liability
                for
                which it intends to seek indemnification from the other Party, the
                Party
                claiming indemnification (the “Indemnitee”)
                shall promptly notify the other Party (the “Indemnitor”)
                and shall permit the Indemnitor, at the Indemnitor’s sole discretion, to
                settle any such claim or suit and agrees to the complete control
                of the
                defense or settlement of such claim or suit by the Indemnitor, and
                the
                Indemnitor shall not be responsible for any legal fees or other costs
                incurred other than as provided in this Agreement. The Indemnitee,
                its
                employees, consultants and agents, shall cooperate fully with the
                Indemnitor and its legal representatives in the investigation and
                defense
                of any claims or suits covered by the indemnification provisions
                of this
                Agreement.

            

    

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          24

          
            

          

        

        
           

        

      

       

    

    ARTICLE
      8

     

    Termination

     

    
      	 	
              8.1

            	
              Either
                party may terminate this Agreement on the occurrence
                of:

            

    

     

    
      	 	
              8.1.1

            	
              The
                bankruptcy or insolvency of the other
                party;

            

    

     

    
      	 	
              8.1.2

            	
              A
                breach by the other party unremedied after [***] notice; or immediately
                by
                a Party on any misappropriation or unauthorized use of its intellectual
                property by the other; 

            

    

     

    
      	 	
              8.1.3

            	
              A
                Party engaging in substantial use of the name of the other party
                without,
                or beyond the scope of, its consent; provided that only the party
                whose
                name was the subject of such improper use may initiate
                termination.

            

    

     

    
      	 	
              8.2

            	
              RGI
                may terminate this Agreement on the occurrence
                of:

            

    

     

    8.2.1 Errors
      in
      SBC’s processing of samples that exceeds similar levels in RGI’s facilities
      elsewhere in the world;  

     

    
      	 	
              8.2.2

            	
              Inability
                to achieve after [***] qualifications necessary for the results of
                its
                analyses to be usable in clinical trials and regulatory submissions
                in
                major markets worldwide, or otherwise as reasonably required to serve
                customers as they may require;

            

    

     

    
      	 	
              8.2.3

            	
              The
                collaboration fails to adequately address quality concerns raised
                by two
                or more customers, as evidenced by customer quality audit results
                or
                customer termination of work for quality related reasons;
                

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          25

          
            

          

        

        
           

        

      

       

    

    
      	 	
              8.2.4

            	
              If
                after good faith negotiations between the Parties, SBC refuses to
                agree on
                a reasonable request for a SOW, RGI shall have the right to terminate
                the
                Agreement; 

            

    

     

    
      	 	
              8.3

            	
              On
                termination, SBC will cease any use of RGI’s Technology, and RGI will
                cease any use of SBC’s proprietary know-how or SOPs for its technology, in
                each instance except as provided in this Article. Unless the termination
                is a result of a breach by SBC under Section 8.1 or 8.2, upon request
                by
                SBC, SBC shall be permitted to use RGI’s proprietary technology used by
                SBC in performance of the Collaboration Services solely for the purpose
                of
                completing any which are required to be performed under contracts
                which
                are in existence as of the date of termination. No additional work
                or
                renewal of such contracts will be permitted. To the extent that SBC
                requests RGI’s assistance in such use of the technology, and RGI agrees to
                provide such assistance, then SBC shall provide appropriate compensation
                to RGI for such assistance.

            

    

     

    
      	 	
              8.4

            	
              If
                RGI terminates this Agreement pursuant to ¶ 8.1 or 8.2 above, RGI shall be
                permitted to use SBC’s proprietary technology used by SBC in performance
                of the Collaboration Services solely for the purpose of completing
                any
                unperformed services for the remainder of the existing Term (with
                no
                renewals permitted). To the extent that RGI requests SBC’s assistance in
                such use of the technology, and SBC agrees to provide such assistance,
                then RGI shall provide appropriate compensation to SBC for such
                assistance.

            

    

     

    
      	 	
              8.5

            	
              In
                the event of termination of this Agreement and/or any Study performed
                under this Agreement, SBC shall use all reasonable efforts to minimize
                any
                further costs and SBC shall be reimbursed only for the Services actually
                performed and the expenses actually and reasonably incurred as of
                the
                effective date of such termination, unless the parties agree or SBC
                is
                otherwise obliged to provide Services after such termination.
                

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          26

          
            

          

        

        
           

        

      

       

    

    
      	 	
              8.6

            	
              Upon
                termination of this Agreement, if requested by the other Party, each
                Party
                shall immediately deliver up to the other Party or, if the other
                Party
                agrees, destroy all copies of and other embodiments of any of the
                Confidential Information and all other correspondence, documents,
                specifications, and any other property belonging to the other Party
                which
                may be in its/his/her possession. One archival copy of such materials
                may
                be maintained in the possession of legal counsel for the
                Party.

            

    

     

    
      	 	
              8.7

            	
              Clauses
                4, 5, 6, 11, 12, and 14 shall survive termination of this Agreement
                for
                whatever reason.

            

    

     

    ARTICLE
      9

     

    Force
      Majeure

     

    
      	 	
              9.1

            	
              In
                this Agreement, “force majeure” shall mean any cause preventing either
                Party from performing any or all of its obligations which arises
                from or
                is attributable to acts, events, omissions or accidents beyond the
                reasonable control of the Party so prevented including, without
                limitation, strikes, lock-outs or other industrial disputes (whether
                involving the workforce of the Party so prevented or of any third
                Party),
                act of God, war, terrorism, riot, civil commotion, malicious damage,
                compliance with any law or Governmental order, rule, regulation or
                direction, accident, breakdown of plant or machinery, fire, flood
                or storm
                (each a “Force Majeure Condition”). Subject to clause 9.3, each Party
                shall be released from its obligations under this Agreement to the
                extent
                that its performance hereunder is delayed, hindered or prevented
                by force
                majeure.

            

    

     

    
      	 	
              9.2

            	
              If
                either Party is prevented or delayed in the performance of any of
                its
                obligations under this Agreement by force majeure, that Party shall
                forthwith serve notice in writing on the other Party specifying the
                nature
                and extent of the circumstances giving rise to force majeure, and
                shall
                subject to service of such notice and to clauses 9.3 and 9.4, have
                no
                liability in respect of the performance of such of its obligations
                as are
                prevented by the force majeure event during the continuation of such
                events, and for such time after they cease as is necessary for that
                Party,
                using all reasonable endeavors, to recommence its affected operations
                in
                order for it to perform its
                obligations.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          27

          
            

          

        

        
           

        

      

       

    

    
      	 	
              9.3

            	
              The
                Party claiming to be prevented or delayed in the performance of any
                of its
                obligations under this Agreement by reason of force majeure shall
                use all
                reasonable endeavors to bring the force majeure event to a close
                or to
                find a solution by which the Agreement may be performed despite the
                continuation of the force majeure
                event.

            

    

     

    
      	 	
              9.4

            	
              If
                either Party is prevented from performance of its obligations for
                a
                continuous period in excess of three (3) months due to force majeure,
                the
                other Party may terminate this Agreement forthwith on service of
                written
                notice upon the Party so prevented, in which case neither Party shall
                have
                any liability to the other except that rights and liabilities which
                accrued prior to such termination shall continue to
                subsist.

            

    

     

    
      	 	
              9.5

            	
              Notwithstanding
                anything in this provision 9 to the contrary, no Force Majeure Condition
                shall relieve RGI of the obligation to pay for Collaboration Services
                which have already been completed by
                SBC.

            

    

     

    ARTICLE
      10

     

    Notice

     

    
      	 	
              10.1

            	
              Any
                notice required by this Agreement to be given to either Party shall
                be in
                writing and shall be served by being addressed to the address of
                the other
                Party stated in this Agreement or such other address as may from
                time to
                time have been notified by a notice given in accordance with this
                clause.
                Any notice or other document to be given under this Agreement shall
                be
                deemed to have been duly given if left at or sent to the address,
                or if
                more than one is listed, to the addresses, referred to in clause
                10.2
                by:

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          28

          
            

          

        

        
           

        

      

       

    

    
      	 	
              10.1.1

            	
              hand
                or courier; 

            

    

     

    
      	 	
              10.1.2

            	
              first
                class post, express or other fast postal service (airmail if abroad);
                or

            

    

     

    
      	 	
              10.1.3

            	
              registered
                post; or 

            

    

     

    
      	 	
              10.1.4

            	
              facsimile
                or other electronic media.

            

    

     

    
      	 	
              10.1.5

            	
              Any
                such notice or other document shall be deemed to have been received
                by the
                addressee two (2) working days following the date of dispatch of
                the
                notice or other document by post (five (5) working days, if sent
                by
                airmail) or, where the notice or other document is sent by hand or
                courier
                or is given by facsimile or other electronic media, simultaneously
                with
                the delivery or transmission. To prove the giving of a notice or
                other
                document it shall be sufficient to show that it was
                dispatched.

            

    

     

    
      	 	
              10.2

            	
              The
                initial details for the purposes of clause 10.1
                are:

            

    

     

    For
      SBC:

    

    Dr.
      Jason
      Gang Jin 

    Senior
      VP
      Global Business Development

    Shanghai
      Biochip Co. Ltd.

    151
      Libing Road, 

    Pudong,
      Shanghai, 201203, China

    

    -
      and
      -

    

    Dr.
      Yaozhou Shi

    Manager
      of Business Development

    Shanghai
      Biochip Co. Ltd.

    151
      Libing Road, 

    Pudong,
      Shanghai, 201203, China

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          29

          
            

          

        

        
           

        

      

       

    -
      and
      -

    

    Dr.
      Jason
      Jin

    President/CEO
      

    MaxyBio
      Corporation

    675
      US
      Highway One

    North
      Brunswick, NJ 08902

    

    For
      RGI:

    

    Kathleen
      Danenberg

    President
      and CEO

    Response
      Genetics, Inc.

    1640
      Marengo Street Suite 600 

    Los
      Angeles, CA 90033 

     

    -and-

     

    Thomas
      Meloro, Esq.

    Willkie
      Farr & Gallagher LLP

    787
      Seventh Avenue

    New
      York,
      NY 10019-6099 

     

    ARTICLE
      11

     

    Governing
      Law and Jurisdiction

     

    
      	 	
              11.1

            	
              The
                law of New York will apply to the agreement(s) establishing the
                collaboration. Exclusive jurisdiction of any disputes under the
                agreement(s) will lie in the Federal and state courts sited in Delaware,
                provided that Response Genetics may at its option commence proceedings
                against SBC in an arbitration under ICC rules, on which election
                all
                disputes arising out of or in connection with the agreement(s) shall
                be
                finally settled under the Rules of Arbitration of the International
                Chamber of Commerce by one or more arbitrators appointed in accordance
                with those Rules. Any hearing related to such arbitration will be
                conducted in Wilmington, Delaware.

            

    

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          30

          
            

          

        

        
           

        

      

       

    

    ARTICLE
      12

     

    Entire
      Agreement, Amendment or Variation

     

    
      	 	
              12.1

            	
              This
                Agreement sets out the entire agreement and understanding between
                the
                Parties regarding the subject matter of this Agreement and supersedes
                all
                prior discussions, arrangements and agreements, whether oral or in
                writing
                or which may be inferred from the conduct of the Parties.
                

            

    

     

    
      	 	
              12.2

            	
              No
                other terms and conditions (including any standard terms and conditions
                of
                SBC, RGI or their Affiliates) shall apply in relation to this Agreement
                or
                the provision of the Collaboration Services or of any other Services
                by
                SBC to RGI, save for any additional terms and conditions specifically
                agreed to in writing hereafter by the
                Parties.

            

    

     

    
      	 	
              12.3

            	
              Any
                amendment or modification to this Agreement shall be made in writing
                and
                signed by both Parties.

            

    

     

     

    ARTICLE
      13

     

    Validity/Severability

     

    
      	 	
              13.1

            	
              The
                invalidity or unenforceability of any provision of this Agreement
                shall
                not affect the validity or enforceability of any other provision,
                which
                shall remain in full force and effect. The Parties shall use their
                reasonable efforts to achieve the purpose of the invalid provision
                by a
                new legally valid stipulation.

            

    

     

     

    ARTICLE
      14

     

    Assignment
      

     

    
      	 	
              14.1

            	
              Neither
                Party may assign its rights and obligations under this Agreement
                without
                the prior written consent of the other. Such written consent shall
                not be
                unreasonably withheld. This Agreement shall be binding upon and shall
                inure to the benefit of the successors and permitted assigns of each
                Party.

            

    

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          31

          
            

          

        

        
           

        

      

       

    

    ARTICLE
      15

     

    Waiver

     

    
      	 	
              15.1

            	
              The
                failure of either Party to exercise any right or remedy under this
                Agreement shall not be deemed to be a waiver of such right or remedy.
                Any
                waiver in respect of any breach of any provision of this Agreement
                which
                is made in writing shall be valid but shall not be construed to be
                a
                waiver of any succeeding breach of such a
                provision.

            

    

     

     

    ARTICLE
      16

     

    Permits

     

    
      	 	
              16.1

            	
              SBC
                shall obtain and pay for all permits, governmental fees, and licenses
                necessary for the Studies to be performed hereunder and shall obtain
                all
                required inspections, authorizations and approvals prior to commencement
                of any Study hereunder. 

            

    

     

     

    ARTICLE
      17

     

    Records

     

    
      	 	
              17.1

            	
              SBC
                agrees to maintain for a period of two years after the termination
                or
                expiration of this Agreement adequate records of, and copies of all
                receipts for expenses incurred in connection with, the performance
                of the
                Services and allow access to RGI and its authorized representatives
                to
                inspect such records and receipts upon reasonable
                notice.

            

    

     

     

    ARTICLE
      18

     

    Laboratory
      Visits

     

    
      	 	
              18.1

            	
              RGI’s
                representatives may visit SBC’s facilities at reasonable times, on
                reasonable prior notice, and with reasonable frequency, during normal
                business hours to observe the progress of the Collaboration Services.
                SBC
                will assist RGI in scheduling such
                visits.

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          32

          
            

          

        

        
           

        

      

       

    

     

    ARTICLE
      19

     

    FDA
      Visits

     

    
      	 	
              19.1

            	
              At
                RGI’s request, a representative of SBC shall accompany RGI to FDA to
                explain or discuss any and all aspects of the Testing Services. Such
                visit
                or visits to the FDA shall be arranged at times mutually agreeable
                to RGI
                and SBC. All reasonable travel and living expenses incurred by SBC
                in
                connection with such visits shall be reimbursed by
                RGI.

            

    

     

    
      	 	
              19.2

            	
              SBC
                shall notify RGI of any request from FDA, other federal or state
                agencies
                or any other Third Party to inspect or otherwise gain access to the
                information, gene expression values, clinical samples, or materials
                pertaining to the services performed by SBC under this Agreement.
                SBC
                shall notify RGI of such request prior to permitting any Third Party
                access, unless prior notice is not reasonably
                feasible.

            

    

     

    
      	 	
              19.3

            	
              SBC
                agrees to permit inspection of such information, gene expression
                values,
                clinical samples, or other materials by authorized representatives
                of FDA
                and as otherwise required by law. During such inspections, SBC shall
                provide appropriate scientific and quality assurance support. SBC
                shall
                promptly send RGI a copy of any inspection reports received by SBC
                as a
                result of any such inspection.

            

    

     

     

    ARTICLE
      20

     

    Counterparts

     

    
      	 	
              20.1

            	
              This
                Agreement may be executed in any number of counterparts, each of
                which
                shall be deemed an original but all of which together shall constitute
                one
                and the same instrument.

            

    

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          33

          
            

          

        

        
           

        

      

       

    

    ARTICLE
      21

     

     

    Exhibits

     

    
      	 	
              21.1

            	
              Any
                Exhibit or SOW to this Agreement is hereby incorporated into and
                made a
                part of this Agreement. In the event of a conflict between the provisions
                contained in this Agreement and any such Exhibit or SOWs, the terms
                of the
                Agreement shall prevail over the Exhibit or SOW, except to the extent
                an
                Exhibit or SOW specifically states that one of its provisions supersedes
                a
                similar provision in the Agreement.

            

    

     

    ARTICLE
      22

     

    Condition
      Precedent

     

    
      	 	
              22.1

            	
              Agreements
                related to the collaboration will not take effect unless and until
                any
                consents necessary for a grant of license rights to Response Genetics
                Technology are obtained, including the consent of USC for RGI to
                sublicense certain USC technology to
                SBC.

            

    

     

    ARTICLE
      23

     

    Governing
      language 

     

    
      	 	
              23.1

            	
              English
                shall be the official language of this Agreement and the English
                language
                shall control for purposes of interpreting its provisions. If translations
                of this Agreement are made, the translation shall be made for the
                conveniences of the Parties only. 

            

    

     

    
      	 	
              23.2

            	
              The
                terms and provisions of any SOW shall be in English and the English
                language shall control for purposes of interpreting the provisions
                of any
                SOW. SBC shall obtain any necessary translation to ensure that the
                SOW and
                any related Standard Operating Procedures are available and understood
                by
                its employees for the performance of the Collaboration Services.
                

            

    

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          34

          
            

          

        

        
           

        

      

       

    

    

    IN
      WITNESS
      whereof
      the Parties have executed this Agreement on the date above written.

    

    Signed
      for and on behalf of Shanghai Biochip Co., Ltd. by

    

    

    _____________________________
      Signature   Date
      _________________   

    Jason
      Gang Jin

    Senior
      Vice President, Global Technology and Business Development

    Shanghai
      Biochip Co.

    

    Signed
      for and on behalf of Response Genetics Inc. by

    

    

    _____________________________
      Signature   Date_________________   

    Kathleen
      Danenberg

    Chief
      Executive Officer

    Response
      Genetics Inc.

     

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          35

          
            

          

        

        
           

        

      

       

    

    Exhibit
      A 

    

    Statement
      of Work

    

    Protocol

    Date

    

    1.0 Title: 

    

    2.0  Study
      Numbers:

     

    3.0 Purpose: 

    

    4.0 Testing
      Facility:  

    

    Study
      Director:  .

    

    5.0 Client:    

    

    Client
      Representative:  

    

    6.0 Proposed
      Study Dates:

    

    Study
      Start Date:  

    

    Study
      Termination Date: 

     

    
      	
              7.0

            	
              Sample
                Type:
                

            

    

     

    Type
      of
      Samples:  

     

    Number
      of
      Samples: 

    

    Precautions: 

    

    Test
      System Justification: 

     

    
      	
              8.0

            	
              Chain
                of Custody Procedure:
                To ensure end-to-end chain-of-custody, the following procedures have
                been
                established and will be followed for all human blood
                samples:

            

    

    
       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          A-1

          
            

          

        

        
           

        

      

       

    
      	
              9.0

            	
              Results
                Report and
                Final Report: 

            

    

    

    
      	
              10.0

            	
              Good
                Laboratory Practice:
                This study will be conducted under the guidelines of Good Laboratory
                Practice as promulgated by the Food and Drug Administration 21 CFR
                58.

            

    

     

    11.0 Approvals

    

    

    _____________________________________ ___________________

    General
      Manager     Date

    

    

    _____________________________________ ___________________

    Vice
      General Manager    Date

    

    

    ____________

    

       

      
        
          
            Portions
              of this Exhibit were omitted and have been filed separately with the
              Secretary
              of the Commission pursuant to the Company’s application requesting confidential
              treatment under Rule 406 of the Securities Act.

             

          

        

        
          A-2Unassociated Document

    

      Exhibit
        10.17

    

    RESPONSE
      GENETICS, INC.

    

    NON-QUALIFIED
      STOCK OPTION AGREEMENT

    

    AGREEMENT
      made as of the __ day of _________ 200_, between Response Genetics, Inc. (the
      “Company”), a Delaware corporation, and _______________ (the
“Participant”).

    

    WHEREAS,
      the Company desires to grant to the Participant an Option to purchase shares
      of
      its common stock, $.01 par value per share (the “Shares”), under and for the
      purposes set forth in the Company’s 2006 Employee, Director and Consultant Stock
      Plan (the “Plan”);

    

    WHEREAS,
      the Company and the Participant understand and agree that any terms used and
      not
      defined herein have the same meanings as in the Plan; and

    

    WHEREAS,
      the Company and the Participant each intend that the Option granted herein
      shall
      be a Non-Qualified Option.

    

    NOW,
      THEREFORE, in consideration of the mutual covenants hereinafter set forth and
      for other good and valuable consideration, the parties hereto agree as
      follows:

    

    
      	 	
              1.

            	
              GRANT
                OF OPTION.

            

    

    

    The
      Company hereby grants to the Participant the right and option to purchase all
      or
      any part of an aggregate of _______________ Shares, on the terms and conditions
      and subject to all the limitations set forth herein, under United States
      securities and tax laws, and in the Plan, which is incorporated herein by
      reference. The Participant acknowledges receipt of a copy of the
      Plan.

    

    
      	 	
              2.

            	
              PURCHASE
                PRICE.

            

    

    

    The
      purchase price of the Shares covered by the Option shall be $_____ per Share,
      subject to adjustment, as provided in the Plan, in the event of a stock split,
      reverse stock split or other events affecting the holders of Shares after the
      date hereof (the “Purchase Price”). Payment shall be made in accordance with
      Paragraph 9 of the Plan.

    

    
      	 	
              3.

            	
              EXERCISABILITY
                OF OPTION.

            

    

    

    Subject
      to the terms and conditions set forth in this Agreement and the Plan, the Option
      granted hereby shall become exercisable as follows:

    

    
      	
              On
                the first anniversary of the date of this Agreement

            	 	
              up
                to ____________ Shares

            
	
              On
                the second anniversary of the date of this Agreement

            	 	
              an
                additional __________ Shares

            

    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

       

    

    
      	
              On
                the third anniversary of the date of this Agreement

            	 	
              an
                additional __________ Shares

            
	
              On
                the fourth anniversary of the date of this Agreement

            	 	
              an
                additional __________ Shares

            

    

    

    The
      foregoing rights are cumulative and are subject to the other terms and
      conditions of this Agreement and the Plan.

    

    Notwithstanding
      the foregoing, in the event of a Change of Control (as defined below), all
      of
      the Shares shall fully accelerate and will be vested for purposes of Section
      24(B) of the Plan unless this Option has otherwise expired or been terminated
      pursuant to its terms or the terms of the Plan.

    

    Change
      of Control
      means
      the occurrence of any of the following events:

    

    
      	 	
              (i)

            	
              Ownership.
                Any “Person” (as such term is used in Sections 13(d) and 14(d) of the
                Securities Exchange Act of 1934, as amended) becomes the “Beneficial
                Owner” (as defined in Rule 13d-3 under said Act), directly or indirectly,
                of securities of the Company representing 50% or more of the total
                voting
                power represented by the Company’s then outstanding voting securities
                (excluding for this purpose the Company or its Affiliates or any
                employee
                benefit plan of the Company) pursuant to a transaction or a series
                of
                related transactions which the Board of Directors does not approve;
                or

            

    

    

    
      	 	
              (ii)

            	
              Merger/Sale
                of Assets. A merger or consolidation of the Company whether or not
                approved by the Board of Directors, other than a merger or consolidation
                which would result in the voting securities of the Company outstanding
                immediately prior thereto continuing to represent (either by remaining
                outstanding or by being converted into voting securities of the surviving
                entity or the parent of such corporation) at least 50% of the total
                voting
                power represented by the voting securities of the Company or such
                surviving entity or parent of such corporation outstanding
                immediately after such merger or consolidation, or the stockholders
                of the
                Company approve an agreement for the sale or disposition by the Company
                of
                all or substantially all of the Company’s assets;
                or

            

    

    

    
      	 	
              (iii)

            	
              Change
                in Board Composition. A change in the composition of the Board of
                Directors, as a result of which fewer than a majority of the directors
                are
                Incumbent Directors. “Incumbent Directors” shall mean directors who either
                (A) are directors of the Company as of the date of this
                Agreement, or (B) are elected, or nominated for election, to the
                Board of Directors with the affirmative votes of at least a majority
                of the Incumbent Directors at the time of such election or nomination
                (but
                shall not include an individual whose election or nomination is in
                connection with an actual or threatened proxy contest relating to
                the
                election of directors to the
                Company).

            

    

    

    
      
        
        

      

      
        2

        
          

        

      

      
        
        

      

       

    

    
      	 	
              4.

            	
              TERM
                OF OPTION.

            

    

    

    The
      Option shall terminate ten years from the date of this Agreement, but shall
      be
      subject to earlier termination as provided herein or in the Plan.

    

    If
      the
      Participant ceases to be an employee, director or consultant of the Company
      or
      of an Affiliate (for any reason other than the death or Disability of the
      Participant or termination of the Participant for “cause” (as defined in the
      Plan)), the Option may be exercised, if it has not previously terminated, within
      three months after the date the Participant ceases to be an employee, director
      or consultant of the Company or an Affiliate, or within the originally
      prescribed term of the Option, whichever is earlier, but may not be exercised
      thereafter. In such event, the Option shall be exercisable only to the extent
      that the Option has become exercisable and is in effect at the date of such
      cessation of service.

    

    Notwithstanding
      the foregoing, in the event of the Participant’s Disability or death within
      three months after the termination of service, the Participant or the
      Participant’s Survivors may exercise the Option within one year after the date
      of the Participant’s termination of service, but in no event after the date of
      expiration of the term of the Option.

    

    In
      the
      event the Participant’s service is terminated by the Company or an Affiliate for
      Cause (as defined in the Plan), the Participant’s right to exercise any
      unexercised portion of this Option shall cease immediately as of the time the
      Participant is notified his or her service is terminated for Cause, and this
      Option shall thereupon terminate. Notwithstanding anything herein to the
      contrary, if subsequent to the Participant’s termination, but prior to the
      exercise of the Option, the Board of Directors of the Company determines that,
      either prior or subsequent to the Participant’s termination, the Participant
      engaged in conduct which would constitute Cause, then the Participant shall
      immediately cease to have any right to exercise the Option and this Option
      shall
      thereupon terminate.

    

    In
      the
      event of the Disability of the Participant, as determined in accordance with
      the
      Plan, the Option shall be exercisable within one year after the Participant’s
      termination of service or, if earlier, within the term originally prescribed
      by
      the Option. In such event, the Option shall be exercisable:

    

    
      	 	
              (a)

            	
              to
                the extent that the Option has become exercisable but has not been
                exercised as of the date of Disability;
                and

            

    

    

    
      	 	
              (b)

            	
              in
                the event rights to exercise the Option accrue periodically, to the
                extent
                of a pro rata portion through the date of Disability of any additional
                vesting rights that would have accrued on the next vesting date had
                the
                Participant not become Disabled. The proration shall be based upon
                the
                number of days accrued in the current vesting period prior to the
                date of
                Disability.

            

    

    

    In
      the
      event of the death of the Participant while an employee, director or consultant
      of the Company or of an Affiliate, the Option shall be exercisable by the
      Participant’s Survivors within one year after the date of death of the
      Participant or, if earlier, within the originally prescribed term of the Option.
      In such event, the Option shall be exercisable:

    

    
      
        
        

      

      
        3

        
          

        

      

      
        
        

      

       

    

    
      	 	
              (x)

            	
              to
                the extent that the Option has become exercisable but has not been
                exercised as of the date of death;
                and

            

    

    

    
      	 	
              (y)

            	
              in
                the event rights to exercise the Option accrue periodically, to the
                extent
                of a pro rata portion through the date of death of any additional
                vesting
                rights that would have accrued on the next vesting date had the
                Participant not died. The proration shall be based upon the number
                of days
                accrued in the current vesting period prior to the Participant’s date of
                death.

            

    

    

    
      	 	
              5.

            	
              METHOD
                OF EXERCISING OPTION.

            

    

    

    Subject
      to the terms and conditions of this Agreement, the Option may be exercised
      by
      written notice to the Company or its designee, in substantially the form of
      Exhibit A
      attached
      hereto. Such notice shall state the number of Shares with respect to which
      the
      Option is being exercised and shall be signed by the person exercising the
      Option. Payment of the purchase price for such Shares shall be made in
      accordance with Paragraph 9 of the Plan. The Company shall deliver such Shares
      as soon as practicable after the notice shall be received, provided, however,
      that the Company may delay issuance of such Shares until completion of any
      action or obtaining of any consent, which the Company deems necessary under
      any
      applicable law (including, without limitation, state securities or “blue sky”
laws). The Shares as to which the Option shall have been so exercised shall
      be
      registered in the Company’s share register in the name of the person so
      exercising the Option (or, if the Option shall be exercised by the Participant
      and if the Participant shall so request in the notice exercising the Option,
      shall be registered in the name of the Participant and another person jointly,
      with right of survivorship) and shall be delivered as provided above to or
      upon
      the written order of the person exercising the Option. In the event the Option
      shall be exercised, pursuant to Section 4 hereof, by any person other than
      the
      Participant, such notice shall be accompanied by appropriate proof of the right
      of such person to exercise the Option. All Shares that shall be purchased upon
      the exercise of the Option as provided herein shall be fully paid and
      nonassessable.

    

    
      	 	
              6.

            	
              PARTIAL
                EXERCISE.

            

    

    

    Exercise
      of this Option to the extent above stated may be made in part at any time and
      from time to time within the above limits, except that no fractional share
      shall
      be issued pursuant to this Option.

    

    
      	 	
              7.

            	
              NON-ASSIGNABILITY.

            

    

    

    The
      Option shall not be transferable by the Participant otherwise than by will
      or by
      the laws of descent and distribution or pursuant to a qualified domestic
      relations order as defined by the Code or Title I of the Employee Retirement
      Income Security Act or the rules thereunder. However, the Participant, with
      the
      approval of the Administrator, may transfer the Option for no consideration
      to
      or for the benefit of the Participant’s Immediate Family (including, without
      limitation, to a trust for the benefit of the Participant’s Immediate Family or
      to a partnership or limited liability company for one or more members of the
      Participant’s Immediate Family), subject to such limits as the Administrator may
      establish, and the transferee shall remain subject to all the terms and
      conditions applicable to the Option prior to such transfer and each such
      transferee shall so acknowledge in writing as a condition precedent to the
      effectiveness of such transfer. Except as provided in the previous sentence,
      the
      Option shall be exercisable, during the Participant’s lifetime, only by the
      Participant (or, in the event of legal incapacity or incompetency, by the
      Participant’s guardian or representative) and shall not be assigned, pledged or
      hypothecated in any way (whether by operation of law or otherwise) and shall
      not
      be subject to execution, attachment or similar process. Any attempted transfer,
      assignment, pledge, hypothecation or other disposition of the Option or of
      any
      rights granted hereunder contrary to the provisions of this Section 7, or the
      levy of any attachment or similar process upon the Option shall be null and
      void. The term “Immediate Family” shall mean the Participant’s spouse, former
      spouse, parents, children, stepchildren, adoptive relationships, sisters,
      brothers, nieces, nephews and grandchildren (and, for this purpose, shall also
      include the Participant.) 

    

    
      
        
        

      

      
        4

        
          

        

      

      
        
        

      

       

    

    
      	 	
              8.

            	
              NO
                RIGHTS AS STOCKHOLDER UNTIL EXERCISE.

            

    

    

    The
      Participant shall have no rights as a stockholder with respect to Shares subject
      to this Agreement until registration of the Shares in the Company’s share
      register in the name of the Participant. Except as is expressly provided in
      the
      Plan with respect to certain changes in the capitalization of the Company,
      no
      adjustment shall be made for dividends or similar rights for which the record
      date is prior to the date of such registration.

    

    
      	 	
              9.

            	
              ADJUSTMENTS.

            

    

    

    The
      Plan
      contains provisions covering the treatment of Options in a number of
      contingencies such as stock splits and mergers. Provisions in the Plan for
      adjustment with respect to stock subject to Options and the related provisions
      with respect to successors to the business of the Company are hereby made
      applicable hereunder and are incorporated herein by reference.  

    

    
      	 	
              10.

            	
              TAXES.

            

    

    

    The
      Participant acknowledges that upon exercise of the Option the Participant will
      be deemed to have taxable income measured by the difference between the then
      fair market value of the Shares received upon exercise and the price paid for
      such Shares pursuant to this Agreement. The Participant acknowledges that any
      income or other taxes due from him or her with respect to this Option or the
      Shares issuable pursuant to this Option shall be the Participant’s
      responsibility.

    

    The
      Participant agrees that the Company may withhold from the Participant’s
      remuneration, if any, the minimum statutory amount of federal, state and local
      withholding taxes attributable to such amount that is considered compensation
      includable in such person’s gross income. At the Company’s discretion, the
      amount required to be withheld may be withheld in cash from such remuneration,
      or in kind from the Shares otherwise deliverable to the Participant on exercise
      of the Option. The Participant further agrees that, if the Company does not
      withhold an amount from the Participant’s remuneration sufficient to satisfy the
      Company’s income tax withholding obligation, the Participant will reimburse the
      Company on demand, in cash, for the amount under-withheld.

    

    
      
        
        

      

      
        5

        
          

        

      

      
        
        

      

       

    

    
      	 	
              11.

            	
              PURCHASE
                FOR INVESTMENT.

            

    

    

    Unless
      the offering and sale of the Shares to be issued upon the particular exercise
      of
      the Option shall have been effectively registered under the Securities Act
      of
      1933, as now in force or hereafter amended (the “1933 Act”), the Company shall
      be under no obligation to issue the Shares covered by such exercise unless
      and
      until the following conditions have been fulfilled:

    

    
      	 	
              (a)

            	
              The
                person(s) who exercise the Option shall warrant to the Company, at
                the
                time of such exercise, that such person(s) are acquiring such Shares
                for
                their own respective accounts, for investment, and not with a view
                to, or
                for sale in connection with, the distribution of any such Shares,
                in which
                event the person(s) acquiring such Shares shall be bound by the provisions
                of the following legend which shall be endorsed upon the certificate(s)
                evidencing the Shares issued pursuant to such
                exercise:

            

    

    

    “The
      shares represented by this certificate have been taken for investment and they
      may not be sold or otherwise transferred by any person, including a pledgee,
      unless (1) either (a) a Registration Statement with respect to such shares
      shall
      be effective under the Securities Act of 1933, as amended, or (b) the Company
      shall have received an opinion of counsel satisfactory to it that an exemption
      from registration under such Act is then available, and (2) there shall have
      been compliance with all applicable state securities laws;” and

    

    
      	 	
              (b)

            	
              If
                the Company so requires, the Company shall have received an opinion
                of its
                counsel that the Shares may be issued upon such particular exercise
                in
                compliance with the 1933 Act without registration thereunder. Without
                limiting the generality of the foregoing, the Company may delay issuance
                of the Shares until completion of any action or obtaining of any
                consent,
                which the Company deems necessary under any applicable law (including
                without limitation state securities or “blue sky”
                laws).

            

    

    

    
      	 	
              12.

            	
              RESTRICTIONS
                ON TRANSFER OF SHARES.

            

    

    

    12.1 The
      Participant agrees that in the event the Company proposes to offer for sale
      to
      the public any of its equity securities and such Participant is requested by
      the
      Company and any underwriter engaged by the Company in connection with such
      offering to sign an agreement restricting the sale or other transfer of Shares,
      then it will promptly sign such agreement and will not transfer, whether in
      privately negotiated transactions or to the public in open market transactions
      or otherwise, any Shares or other securities of the Company held by him or
      her
      during such period as is determined by the Company and the underwriters, not
      to
      exceed 90 days following the closing of the offering, plus such additional
      period of time as may be required to comply with Marketplace Rule 2711 of the
      National Association of Securities Dealers, Inc. or similar rules thereto (such
      period, the “Lock-Up Period”). Such agreement shall be in writing and in form
      and substance reasonably satisfactory to the Company and such underwriter and
      pursuant to customary and prevailing terms and conditions. Notwithstanding
      whether the Participant has signed such an agreement, the Company may impose
      stop-transfer instructions with respect to the Shares or other securities of
      the
      Company subject to the foregoing restrictions until the end of the Lock-Up
      Period.

    

    
      
        
        

      

      
        6

        
          

        

      

      
        
        

      

       

    

    12.2 The
      Participant acknowledges and agrees that neither the Company, its shareholders
      nor its directors and officers, has any duty or obligation to disclose to the
      Participant any material information regarding the business of the Company
      or
      affecting the value of the Shares before, at the time of, or following a
      termination of the employment of the Participant by the Company, including,
      without limitation, any information concerning plans for the Company to make
      a
      public offering of its securities or to be acquired by or merged with or into
      another firm or entity.

    

    
      	 	
              13.

            	
              NO
                OBLIGATION TO MAINTAIN RELATIONSHIP.

            

    

    

    The
      Company is not by the Plan or this Option obligated to continue the Participant
      as an employee, director or consultant of the Company or an Affiliate. The
      Participant acknowledges: (i) that the Plan is discretionary in nature and
      may
      be suspended or terminated by the Company at any time; (ii) that the grant
      of
      the Option is a one-time benefit which does not create any contractual or other
      right to receive future grants of options, or benefits in lieu of options;
      (iii)
      that all determinations with respect to any such future grants, including,
      but
      not limited to, the times when options shall be granted, the number of shares
      subject to each option, the option price, and the time or times when each option
      shall be exercisable, will be at the sole discretion of the Company; (iv) that
      the Participant’s participation in the Plan is voluntary; (v) that the value of
      the Option is an extraordinary item of compensation which is outside the scope
      of the Participant’s employment contract, if any; and (vi) that the Option is
      not part of normal or expected compensation for purposes of calculating any
      severance, resignation, redundancy, end of service payments, bonuses,
      long-service awards, pension or retirement benefits or similar
      payments.

    

    
      	 	
              14.

            	
              NOTICES.

            

    

    

    Any
      notices required or permitted by the terms of this Agreement or the Plan shall
      be given by recognized courier service, facsimile, registered or certified
      mail,
      return receipt requested, addressed as follows:

    

    If
      to the
      Company:

    Response
      Genetics, Inc. 

    Attn:
      Finance

    1640
      Marengo Street, 

    Los
      Angeles, CA 90033

    

    If
      to the
      Participant:

    
      	 
	 
	 

    

    

    or
      to
      such other address or addresses of which notice in the same manner has
      previously been given. Any such notice shall be deemed to have been given upon
      the earlier of receipt, one business day following delivery to a recognized
      courier service or three business days following mailing by registered or
      certified mail.

    

    
      
        
        

      

      
        7

        
          

        

      

      
        
        

      

       

    

    
      	 	
              15.

            	
              GOVERNING
                LAW.

            

    

    

    This
      Agreement shall be construed and enforced in accordance with the law of the
      State Delaware, without giving effect to the conflict of law principles thereof.
      

    

    
      	 	
              16.

            	
              BENEFIT
                OF AGREEMENT.

            

    

    

    Subject
      to the provisions of the Plan and the other provisions hereof, this Agreement
      shall be for the benefit of and shall be binding upon the heirs, executors,
      administrators, successors and assigns of the parties hereto.

    

    
      	 	
              17.

            	
              ENTIRE
                AGREEMENT.

            

    

    

    This
      Agreement, together with the Plan, embodies the entire agreement and
      understanding between the parties hereto with respect to the subject matter
      hereof and supersedes all prior oral or written agreements and understandings
      relating to the subject matter hereof. No statement, representation, warranty,
      covenant or agreement not expressly set forth in this Agreement shall affect
      or
      be used to interpret, change or restrict, the express terms and provisions
      of
      this Agreement, provided, however, in any event, this Agreement shall be subject
      to and governed by the Plan.

    

    
      	 	
              18.

            	
              MODIFICATIONS
                AND AMENDMENTS.

            

    

    

    The
      terms
      and provisions of this Agreement may be modified or amended as provided in
      the
      Plan.

    

    
      	 	
              19.

            	
              WAIVERS
                AND CONSENTS.

            

    

    

    Except
      as
      provided in the Plan, the terms and provisions of this Agreement may be waived,
      or consent for the departure therefrom granted, only by written document
      executed by the party entitled to the benefits of such terms or provisions.
      No
      such waiver or consent shall be deemed to be or shall constitute a waiver or
      consent with respect to any other terms or provisions of this Agreement, whether
      or not similar. Each such waiver or consent shall be effective only in the
      specific instance and for the purpose for which it was given, and shall not
      constitute a continuing waiver or consent.

    

    
      	
            	20.	
              DATA
                PRIVACY.

            

    

    

    By
      entering into this Agreement, the Participant: (i) authorizes the Company and
      each Affiliate, and any agent of the Company or any Affiliate administering
      the
      Plan or providing Plan recordkeeping services, to disclose to the Company or
      any
      of its Affiliates such information and data as the Company or any such Affiliate
      shall request in order to facilitate the grant of options and the administration
      of the Plan; (ii) waives any data privacy rights he or she may have with respect
      to such information; and (iii) authorizes the Company and each Affiliate to
      store and transmit such information in electronic form.

    

    
      
        
        

      

      
        8

        
          

        

      

      
        
        

      

    

    

    [Remainder
      of Page Intentionally Left Blank]

    

    
      
        
        

      

      
        9

        
          

        

      

      
        
        

      

       

    

    IN
      WITNESS WHEREOF, the Company has caused this Agreement to be executed by its
      duly authorized officer, and the Participant has hereunto set his or her hand,
      all as of the day and year first above written.

     

     

    
      	 	
              Response
                Genetics, Inc.

              

              

              By: 
                _______________________________

              Name

              Title

              
 

              ___________________________________
Participant

            

    

    
 

    
      
        
        

      

      
        10

        
          

        

      

      
        
        

      

    

     

    Exhibit
      A

    

    NOTICE
      OF
      EXERCISE OF NON-QUALIFIED STOCK OPTION

    

    
      	TO:	
              Response
                Genetics, Inc.

            

    

    

    Ladies
      and Gentlemen:

    

    I
      hereby
      exercise my Non-Qualified Stock Option to purchase _________ shares (the
“Shares”) of the common stock, $.01 par value, of Response Genetics,
      Inc. (the
      “Company”), at the exercise price of $________ per share, pursuant to and
      subject to the terms of that certain Non-Qualified Stock Option Agreement
      between the undersigned and the Company dated _______________,
      200_.

    

    I
      understand the nature of the investment I am making and the financial risks
      thereof. I am aware that it is my responsibility to have consulted with
      competent tax and legal advisors about the relevant national, state and local
      income tax and securities laws affecting the exercise of the Option and the
      purchase and subsequent sale of the Shares.

    

    I
      am
      paying the option exercise price for the Shares as follows:

    

    _________________________________________

    

    

    Please
      issue the Shares (check one):

    

    o 
to
      me; or

    

    o 
to
      me and
      ____________________________, as joint tenants with right of
      survivorship,

    

    at
      the
      following address:

    

    
      	 
	 
	 

    

    

    My
      mailing address for shareholder communications, if different from the address
      listed above, is:

    

    
      	 
	 
	 

    
      
        
        

      

      
        A-1

        
          

        

      

      
        
        

      

    

     

    
      	 	
              Very
                truly yours,

              

              
__________________________________

              Participant
                (signature)

              

              
__________________________________

              Print
                Name

              

              
__________________________________

              Date

              

              
__________________________________

              Social
                Security Number

            

    

     

    
      
        
        

      

      
        A-2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00122-of-00352.parquet"}]]